Receptor Integral To Or Derived From A Lymphocytic Or Lymphocytic-like Cell (e.g., Nk Cell, Etc.) Patents (Class 424/144.1)
  • Patent number: 10350242
    Abstract: The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutrititive media up to about 72 hours. The storage method enables the cells to be manufactured at a processing facility and shipped to a point of care site. The invention also includes compositions that have been stored in non-nutritive buffer at storage temperatures while maintaining the functional characteristics.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: July 16, 2019
    Assignee: IMMUNOVATIVE THERAPIES LTD.
    Inventor: Michael Har-Noy
  • Patent number: 10336829
    Abstract: Provided are compounds having the Formula I: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the intracellular delivery of antibodies.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: July 2, 2019
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar Jörg Floris Kaufmann, Heehyoung Lee, Ingale Sampat Lalaso
  • Patent number: 10316085
    Abstract: The present invention relates in part to the discovery of genes that are deregulated in cancer stem cells (e.g., melanoma stem cells). In some aspects, methods for treating individuals having melanoma are provided; the methods involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes. In other aspects, cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. Other aspects of the invention relate to reagents, arrays, compositions, and kits that are useful for diagnosing and treating melanoma.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: June 11, 2019
    Assignee: Children's Medical Center Corporation
    Inventors: Markus H. Frank, Natasha Y. Frank
  • Patent number: 10316095
    Abstract: Formulations of anti-VLA-1 antibodies are described.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: June 11, 2019
    Assignee: Santarus, Inc.
    Inventors: Adam Jeremy Fowler, Craig Michael Bowe, Wayne Curtis Yount, Nathan Jeremy Cobb, Timothy Martin Kelly
  • Patent number: 10293059
    Abstract: This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding a therapeutic gene that blocks allergic reactions. The invention is also directed to a composition comprising the vector and method of using the vector to reduce or inhibit an immune response or allergic reaction to an allergen in a mammal.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: May 21, 2019
    Assignee: CORNELL UNIVERSITY
    Inventors: Ronald G. Crystal, Odelya E. Pagovich, Maria J. Chiuchiolo
  • Patent number: 10287356
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: May 14, 2019
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • Patent number: 10280208
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 7, 2019
    Assignee: Albert Einstein College of Medicine
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
  • Patent number: 10253095
    Abstract: Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: April 9, 2019
    Assignees: INNATE PHARMA S.A.S., NOVO NORDISK A/S
    Inventors: Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Joakim Glamann
  • Patent number: 10245327
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 2, 2019
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 10246510
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: April 2, 2019
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Benjamin Rossi, Hélène Sicard, Carine Paturel
  • Patent number: 10196616
    Abstract: An altered avian NDV that contains the coding sequence of avian interleukin-4 (IL-4), or a portion thereof, in the reverse orientation suppresses in-ovo IL-4 production via RNAi when administered to embryonic birds. An immunogenic composition containing this altered NDV is included in this invention. The altered avian NDV can, optionally contain a polynucleotide encoding a heterologous antigen from a heterologous avian pathogen and can produce said heterologous antigen in-ovo.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: February 5, 2019
    Assignees: The United States of America, as represented by the Secretary of Agriculture, University of Georgia Research Foundation, Inc.
    Inventors: Claudio L. Afonso, Valerie C. Marcano, Nany Stivalis Cardenas Garcia, Qingzhong Yu, Tonya L. Taylor
  • Patent number: 10189906
    Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: January 29, 2019
    Assignee: MAX-DELRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
    Inventors: Martin Lipp, Felix Oden, Uta Höpken, Gerd Müller, Oliver Daumke, Stephen Marino, Daniel Olal
  • Patent number: 10174124
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: January 8, 2019
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Robert F. Kelley, Mary A. Mathieu, Liping L. Sun
  • Patent number: 10106607
    Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies againstcanine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 23, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • Patent number: 10086046
    Abstract: The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory T cells (TReg) in an organism and various methods in which the agents according to the invention are used.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: October 2, 2018
    Assignee: AiCuris GmbH & Co. KG
    Inventors: Daniela Paulsen, Nina Brunner, Dorothy Bray
  • Patent number: 10086042
    Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: October 2, 2018
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva, Neal Schilling
  • Patent number: 10077312
    Abstract: The present invention relates to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to IL23R-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in treating inflammatory and/or autoimmune diseases and/or cancer.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: September 18, 2018
    Assignee: Numab Therapeutics AG
    Inventors: David Urech, Tea Gunde, Sebastian Meyer
  • Patent number: 10034939
    Abstract: In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7. The inventors particularly observed a major synergistic effect of combining anti-CTLA-4 with either an IDO inhibitor, with anti-PD-L1 mAb, or with CD-25 depletion. Such combinations have been found to demonstrate a synergistic effect in treating cancer and tumors, for example by reducing tumor size, increasing the percentage of antigen-specific T cells, and increasing T cell function.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: July 31, 2018
    Assignee: The University of Chicago
    Inventors: Thomas F. Gajewski, Stefani Spranger, Michael Leung
  • Patent number: 10016458
    Abstract: The invention provides, inter alia, methods for treating vascular deficiencies, including those in diabetic subjects, by transplanting endothelial progenitor cells with transiently reduced p53 expression.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: July 10, 2018
    Assignee: Baystate Health, Inc.
    Inventor: Sabyasachi Sen
  • Patent number: 10000545
    Abstract: The present invention concerns the use of an inhibitor of an interaction between type IV pilus-associated protein and CD147 for preventing or treating meningoccal bacteraemia and/or infection. The present invention also relates to the combined use of such inhibitor and of an anti-bacterial compound, such as one used to prevent or treat a meningococcal infection. The invention also relates to a method for the prevention and/or treatment of meningococcal bacteraemia and/or infection, and to a method for screening inhibitors of the interaction between type IV pilus-associated protein and CD147.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: June 19, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS DESCARTES
    Inventors: Xavier Nassif, Sandrine Bourdoulous, Olivier Join-Lambert
  • Patent number: 9982023
    Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: May 29, 2018
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Carl F. Ware, John Sedy
  • Patent number: 9963508
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: May 8, 2018
    Assignees: AMGEN FREMONT INC., PFIZER INC.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Patent number: 9963497
    Abstract: The present disclosure relates to a method for the treatment of a non-pathogen associated inflammatory disorders in a subject in need thereof, comprising administering to said subject an isolated peptide which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member, particularly the T cell costimulatory pathway members CD28 and CTLA4. The present disclosure also relates to pharmaceutical compositions comprising the isolated peptide and to use of the peptide in treating of a non-pathogen associated inflammatory disorders.
    Type: Grant
    Filed: December 7, 2014
    Date of Patent: May 8, 2018
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD, ATOX BIO LTD.
    Inventors: Raymond Kaempfer, Anat Shirvan, Gila Arad
  • Patent number: 9950035
    Abstract: Methods for making non-immunogenic anti-inflammatory cytokine compositions, comprising (a) obtaining a liquid comprising cytokine producing cells from a mammalian donor; (b) contacting the liquid with a solid extraction material to generate a composition rich in interleukin-1 receptor antagonist; and performing one or both of (i) removing cells from the composition and (ii) freezing the composition. The compositions comprise two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII, Compositions may also contain white blood cells and platelets.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 24, 2018
    Assignee: Biomet Biologics, LLC
    Inventors: Jeffrey R. Binder, Joel C. Higgins, Michael D. Leach, Krista O'Shaughnessey, Jennifer E. Woodell-May
  • Patent number: 9932402
    Abstract: Methods of treatment to suppress an immune response are provided. The method comprises administering to a subject in need of treatment a naked blocking antibody that binds selectively iNKT cells in an amount effective to suppress the subject's iNKT cell function. Compositions comprising, an isolated, humanized antibody that binds selectively iNKT cells are also provided.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 3, 2018
    Assignee: NKT Therapeutics Inc.
    Inventors: Alemseged Truneh, Francis Joseph Carr, Timothy David Jones, James P. Gregson
  • Patent number: 9913830
    Abstract: The present invention provides nanoparticle-coupled tolerogenic Treg cell therapy for treatment of immune and/or autoimmune disorders. In certain specific embodiments, the present invention can be used in the prevention and/or treatment of autoimmune diseases including, but not limited to, type 1 diabetes, lupus erythematosus (SLE), multiple sclerosis (MS), inflammatory bowel disease (IBD), rheumatoid arthritis, oophoritis, and autoimmune pathology associated with Graft versus Host Disease (GvHD) following hematopoietic stem cell transplantation.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: March 13, 2018
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Todd M. Brusko, Benjamin G. Keselowsky, Judit Cserny
  • Patent number: 9880179
    Abstract: Provided herein are several methods for selecting agents that bind to transmembrane receptors in a conformationally-selective way. In some embodiments, the method may comprise producing: a transmembrane receptor in an active conformation; and said transmembrane receptor in an inactive conformation and using cell sorting to select, from a population of cells comprising a library of cell surface-tethered extracellular capture agents, cells that are specifically bound to either the transmembrane receptor in its active conformation or the transmembrane receptor in its inactive conformation, but not both. In other embodiments, the method may comprise: contacting a GPCR with a population of cells that comprise a library of surface-tethered extracellular proteins; labeling the cell population with a conformationally-specific binding agent, e.g., a G-protein or mimetic thereof; and using cell sorting to select from the cell population cells that bind to the agent.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: January 30, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Aaron Michael Ring, Aashish Manglik, Andrew Kruse, Brian Kobilka
  • Patent number: 9867832
    Abstract: The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and/or for inducing differentiation into regulator T cells from undifferentiated T cells and/or promoting proliferation of regulator T cells.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: January 16, 2018
    Assignee: LG CHEM, LTD.
    Inventors: Seok Goo Cho, Na Youn Kim, Eun Jung Kim, Keon Il Im, Jung Yeon Lim, Eun Joo Jeon
  • Patent number: 9868961
    Abstract: The present invention provides compositions and methods for effectuating the localized expression of anti-CTLA-4 antibody proximal to a target tissue in a patient.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: January 16, 2018
    Assignee: The Regents of the University of California
    Inventors: James Allison, Michael Curran
  • Patent number: 9840559
    Abstract: The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: December 12, 2017
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNIVERSITY OF QUEENSLAND, DENDROCYTE BIOTECH PTY LTD
    Inventors: Therese Ann Seldon, David John Munster, Derek Nigel John Hart, Martina Louise Jones, Trent Phillip Munro, Stephen Michael Mahler, Eunice Yu Zhou, James D. Marks
  • Patent number: 9801929
    Abstract: An object of the present invention is to provide a drug and a method for effectively inducing donor-specific immune tolerance in a recipient in transplantation therapy. A complex of an siRNA for a costimulatory factor and schizophyllan is delivered to a Dectin-1 expressing cell which specifically recognizes schizophyllan to regulate the function of the Dectin-1 expressing cell, and therefore can induce immunosuppression effect as well as induce immune tolerance effectively.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: October 31, 2017
    Assignee: Napajen Pharma, Inc.
    Inventors: Ko Rii, Kazuo Sakurai, Masakazu Kobayashi, Hironori Ando, Sadaharu Higuchi, Shiro Takahara
  • Patent number: 9790274
    Abstract: Embodiments of the invention provide high affinity recombinant EpCAM-binding antibodies. Methods of using a such antibodies as imaging agents, diagnostics and therapeutics are also provided. Dual-nuclear and fluorescently labeled or singly fluorescently labeled contrast agents promise the advantage of molecularly-guided surgical resection via surgical field near-infrared fluorescence (NIRF) imaging following (in the case of dual labeled agents) nuclear imaging for general localization. Currently, nodal staging of most cancers is performed following lymph node (LN) biopsy and dissection for subsequent pathological examination.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 17, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Barrett R. Harvey, Kenneth L. Pinkston, Ali Azhdarina, Eva M. Sevick-Muraca
  • Patent number: 9790275
    Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 17, 2017
    Assignee: Stichting Sanquin Bloedvoorziening
    Inventor: Timo Kars Van Den Berg
  • Patent number: 9790278
    Abstract: Antibodies, chimeric antigen receptors, and bispecific T-cell engagers having specificity for B7-H6 and methods for using the same in the diagnosis and treatment of disorders associated with B7-H6 expression are provided.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: October 17, 2017
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Charles L. Sentman, Tong Zhang
  • Patent number: 9757473
    Abstract: A cell-penetrating peptide, a conjugate of the cell-penetrating peptide with an anticancer agent, and a composition comprising the conjugate is described. An effective means for transferring a cancer-specific anticancer agent can be provided by using the cell-penetrating peptide. More particularly, by preparing the conjugate of the present invention wherein the cell-penetrating peptide and the anticancer agent are combined, the application concentration of a conventional anticancer agent can be reduced and cancer specificity can be provided, and thus an effect of reducing side effects during the treatment process can be obtained.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: September 12, 2017
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 9758589
    Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: September 12, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • Patent number: 9731001
    Abstract: The invention is concerned with compounds, pharmaceutical compositions, screening methods, and therapeutic methods for preventing or reducing a human immunodeficiency virus type-1 (HIV-1) infection and/or propagation associated with dendritic cell immunoreceptor (DCIR). Described herein are compounds which bind on at least one three-dimensional cavity of the DCIR, the cavity(ies) being involved in the interaction between HIV-1 and DCIR. Also described are screening methods for identifying active inhibitors and method of using such inhibitors for the prevention or treatment of virus infections, and more particularly for reducing human immunodeficiency virus type-1 (HIV-1) binding, entry and/or replication in human cells.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: August 15, 2017
    Assignee: Universite Laval
    Inventors: Caroline Gilbert, Michel J. Tremblay, Sheng-Xiang Lin, Arezki Azzi, Alexandra Lambert
  • Patent number: 9732149
    Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: August 15, 2017
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Leonard Bell, Russell P. Rother, Mark J. Evans
  • Patent number: 9713636
    Abstract: A highly stable nucleic acid-polysaccharide complex of an siRNA and schizophyllan is formed by adding polydeoxyadenine in which at least part of the phosphodiester link portion is phosphorothioated to an siRNA and allowing the siRNA and schizophyllan to form a complex.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: July 25, 2017
    Assignee: NAPAJEN PHARMA, INC.
    Inventors: Ko Rii, Kazuo Sakurai, Masakazu Kobayashi, Hironori Ando, Sadaharu Higuchi, Shiro Takahara
  • Patent number: 9657068
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: May 23, 2017
    Assignee: Ultimovacs AS
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Patent number: 9657094
    Abstract: Methods, processes, systems, and compositions for treating disease are disclosed. In some cases, the present disclosure provides for delivery of therapeutic agents, in an active form, to a localized area, over an extended period of time. In one embodiment, the disclosed composition may comprise a therapeutic agent and a biodegradable polymer and/or a biodegradable polymer microsphere.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: May 23, 2017
    Assignee: Colorado School of Mines
    Inventor: Melissa D. Krebs
  • Patent number: 9642910
    Abstract: The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 (also known as human T lymphotropic virus type-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: May 9, 2017
    Assignees: St. Marianna University School of Medicine, KYOWA HAKKO KIRIN CO., LTD
    Inventor: Yoshihisa Yamano
  • Patent number: 9593147
    Abstract: This invention relates to: a peptide which comprises an amino acid sequence consisting of 12 to 18 amino acid residues represented by (X1-3)—C—(X8-10)—C—(X1-3) wherein each X independently represents an arbitrary amino acid residue other than cysteine, and C represents a cysteine residue, and is capable of binding to human IgA; and to a method for analyzing or purifying human IgA using the peptide.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: March 14, 2017
    Assignees: Kagoshima University, Otsuka Chemical Co., Ltd.
    Inventor: Yuji Ito
  • Patent number: 9567367
    Abstract: Disclosed are peptides and methods for the treatment of bacterial infections and associated inflammation. Effective doses and treatment protocols are disclosed.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: February 14, 2017
    Assignee: ATOX BIO LTD.
    Inventors: Anat Shirvan, Dan Teleman, Gila Arad, Raymond Kaempfer
  • Patent number: 9562098
    Abstract: The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 7, 2017
    Assignees: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Caroline Mary, Nicolas Poirier, Bernard Vanhove
  • Patent number: 9556279
    Abstract: Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: January 31, 2017
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Rinpei Niwa, Mami Tsuchiya
  • Patent number: 9540433
    Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: January 10, 2017
    Assignee: GENMAB A/S
    Inventors: Sandra Verploegen, Marije Overdijk, Riemke Van Dijkhuizen, Willem Karel Bleeker, Patrick Van Berkel, Paul Parren, Steen Lisby
  • Patent number: 9526702
    Abstract: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 27, 2016
    Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc., President and Fellows of Harvard College, The Children's Medical Center Corporation
    Inventors: Ulrich H. von Andrian, Omid C. Farokhzad, Robert S. Langer, Tobias Junt, Elliott Ashley Moseman, Liangfang Zhang, Pamela Basto, Matteo Iannacone, Frank Alexis
  • Patent number: 9434785
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: September 6, 2016
    Assignee: Kymab Limited
    Inventors: Philip Bland-Ward, Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac, Leslie Susan Kean, Victor Tkachev
  • Patent number: 9427463
    Abstract: The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent. Such methods find utility in the treatment of certain subsets of malignant neoplastic cell proliferative disorders or diseases, e.g. renal cell carcinoma and melanoma. The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: August 30, 2016
    Assignee: Cedars-Sinai Medical Center
    Inventors: Hyung Kim, Yanping Wang